search
STK-002
Trends
- 1Stoke Therapeutics to Present STK-002 Data at AAO 2026▼Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Stoke Therapeutics said its investigational therapy STK-002, being developed for autosomal dominant optic atrophy, a rare genetic eye disease that causes progressive vision loss, will be featured in presentations at the American Academy of Ophthalmology 2026 Annual Meeting. The company made the announcement ahead of the meeting; details of the study results have not yet been reported.